Common Infections — MCQs
On this page
A 67-year-old man with a history of chronic venous insufficiency develops cellulitis of his right lower leg and is treated with oral flucloxacillin. This is his fourth episode in 18 months, all affecting the same leg. Between episodes, he has no fever or active infection but has persistent leg swelling and varicose eczema. What is the most appropriate long-term antimicrobial stewardship-aligned strategy to reduce recurrence?
A 46-year-old man undergoes elective inguinal hernia repair as a day case procedure. He receives a single dose of intravenous co-amoxiclav 1.2g at induction of anaesthesia at 09:00. The procedure lasts 45 minutes and is uncomplicated with primary closure. He is recovering well post-operatively and due for discharge at 16:00. The surgical team writes him a prescription for co-amoxiclav 625mg three times daily for 5 days 'to complete the course and prevent wound infection'. From an antimicrobial stewardship perspective, what is the most appropriate action?
What is the recommended first-line oral antibiotic for the treatment of uncomplicated cellulitis in adults according to current UK national guidance?
A hospital trust antimicrobial stewardship team reviews prescribing practices on surgical wards and identifies that 68% of patients receive surgical antibiotic prophylaxis extending beyond 24 hours post-operatively, despite evidence that single-dose prophylaxis is adequate for most procedures. Which quality improvement intervention has the strongest evidence base for reducing inappropriate prolonged surgical prophylaxis?
A 58-year-old woman with poorly controlled type 2 diabetes (HbA1c 98 mmol/mol) presents with a 24-hour history of rapidly progressive pain, swelling, and discolouration of her left foot following a minor injury 3 days ago. On examination, the foot is grossly swollen, dusky purple with areas of blistering, and there is crepitus on palpation. She appears unwell with temperature 38.9°C, pulse 118 bpm, blood pressure 98/62 mmHg. Blood tests show: WBC 22.4 × 10⁹/L, lactate 4.8 mmol/L, creatinine 156 μmol/L, CK 2,840 U/L. What is the most critical immediate antimicrobial therapy in addition to urgent surgical consultation?
A 26-year-old man presents with a 4-day history of multiple painful pustular lesions on his forearms, chest, and back. He is an amateur rugby player and reports that several teammates have had similar skin problems. Examination reveals multiple 1-2 cm diameter lesions with surrounding erythema and central pustulation. Some lesions have yellow crusting. Temperature 37.4°C, otherwise systemically well. A swab from one lesion grows Staphylococcus aureus resistant to flucloxacillin but sensitive to erythromycin, doxycycline, and co-trimoxazole. What is the most appropriate management?
A hospital antimicrobial stewardship committee is evaluating the impact of a newly implemented antibiotic approval system for restricted antimicrobials. Six months after implementation, audit data shows: total antibiotic prescriptions reduced by 12%, restricted antibiotic use reduced by 35%, mean duration of therapy reduced from 8.2 to 6.4 days, but Clostridioides difficile infection rates increased from 2.1 to 3.8 per 10,000 bed-days. Hospital-acquired bacteraemia rates remain unchanged. What is the most appropriate interpretation of these findings?
A 34-year-old woman with a BMI of 38 kg/m² presents to the Emergency Department with a 3-day history of a painful, red, swollen area on the inner aspect of her right thigh. The affected area measures approximately 15 cm × 10 cm, is warm and tender with overlying shiny skin, but there is no fluctuance, crepitus, or systemic upset. Temperature 37.2°C, pulse 78 bpm, blood pressure 128/82 mmHg. What is the most appropriate immediate management according to current UK guidance?
According to the UK 'Start Smart - Then Focus' antimicrobial stewardship toolkit, which of the following constitutes a key component of the 'Review' decision at 48-72 hours?
A 72-year-old man with chronic obstructive pulmonary disease is admitted with an acute exacerbation and started on intravenous co-amoxiclav. On day 4, he develops profuse watery diarrhoea (8 episodes in 24 hours) with cramping abdominal pain. Temperature is 38.3°C, pulse 102 bpm, blood pressure 118/72 mmHg. Examination reveals a diffusely tender abdomen without peritonism. Blood tests show WBC 16.2 × 10⁹/L, CRP 145 mg/L, creatinine 142 μmol/L (baseline 98 μmol/L). According to UK antimicrobial stewardship principles, what is the most appropriate initial management?
Common Infections UK Medical PG Practice Questions and MCQs
Question 161: A 67-year-old man with a history of chronic venous insufficiency develops cellulitis of his right lower leg and is treated with oral flucloxacillin. This is his fourth episode in 18 months, all affecting the same leg. Between episodes, he has no fever or active infection but has persistent leg swelling and varicose eczema. What is the most appropriate long-term antimicrobial stewardship-aligned strategy to reduce recurrence?
- A. Prophylactic oral flucloxacillin 250mg twice daily indefinitely
- B. Prophylactic oral phenoxymethylpenicillin 500mg twice daily for 12 months with review (Correct Answer)
- C. Rotating courses of different antibiotics (flucloxacillin, doxycycline, clarithromycin) every 3 months to prevent resistance
- D. Topical fusidic acid to the affected leg applied daily as long-term prophylaxis
- E. No antibiotic prophylaxis; focus on compression therapy, skin care, and management of venous insufficiency with antibiotic treatment only for acute episodes
Explanation: ***Prophylactic oral phenoxymethylpenicillin 500mg twice daily for 12 months with review*** - Antibiotic prophylaxis is indicated for patients who experience **two or more episodes** of cellulitis per year, particularly when underlying risk factors like **chronic venous insufficiency** are present. This patient has had four episodes in 18 months. - **Phenoxymethylpenicillin** (Penicillin V) is the preferred agent because it is **narrow-spectrum** and primarily targets **Streptococci**, which are the most common causative organisms for recurrent cellulitis, aligning with **antimicrobial stewardship** principles. The duration of 12 months with a review is also standard practice. *Prophylactic oral flucloxacillin 250mg twice daily indefinitely* - While **flucloxacillin** is effective for acute cellulitis (often due to *Staphylococcus aureus* or *Streptococcus pyogenes*), its use for long-term prophylaxis is less preferred due to its **broader spectrum** compared to phenoxymethylpenicillin, which may lead to unnecessary impact on normal flora and increased resistance risk. - Indefinite therapy without review is generally discouraged for antibiotic prophylaxis. Guidelines typically recommend a periodic **clinical review** (e.g., every 6–12 months) to assess the continued need and potential for discontinuation. *Rotating courses of different antibiotics (flucloxacillin, doxycycline, clarithromycin) every 3 months to prevent resistance* - There is no clinical evidence to support **rotating antibiotics** for cellulitis prophylaxis; this practice is more likely to increase the selection pressure for **multi-drug resistant** organisms rather than prevent resistance. - **Antimicrobial stewardship** principles emphasize using the **narrowest-spectrum** agent consistently when prophylaxis is indicated, rather than cycling through various broad-spectrum antibiotics. *Topical fusidic acid to the affected leg applied daily as long-term prophylaxis* - **Topical antibiotics** like fusidic acid are not indicated for the prevention of systemic infections like cellulitis, which originates from deeper tissue layers. They have poor penetration and do not achieve therapeutic levels systemically. - Long-term topical antibiotic use significantly increases the risk of developing **bacterial resistance** (especially to *Staphylococcus aureus* leading to MRSA) and can also cause **contact dermatitis** or sensitization. *No antibiotic prophylaxis; focus on compression therapy, skin care, and management of venous insufficiency with antibiotic treatment only for acute episodes* - While **compression therapy**, meticulous **skin care**, and aggressive management of **venous insufficiency** are crucial in preventing cellulitis recurrence by addressing underlying predisposing factors, this patient's history of **four episodes in 18 months** clearly meets the threshold for recommending **antibiotic prophylaxis**. - For patients with frequent recurrent cellulitis, relying solely on reactive treatment for acute episodes is insufficient and can lead to repeated hospitalizations, increased morbidity, and cumulative **lymphatic damage**.
Question 162: A 46-year-old man undergoes elective inguinal hernia repair as a day case procedure. He receives a single dose of intravenous co-amoxiclav 1.2g at induction of anaesthesia at 09:00. The procedure lasts 45 minutes and is uncomplicated with primary closure. He is recovering well post-operatively and due for discharge at 16:00. The surgical team writes him a prescription for co-amoxiclav 625mg three times daily for 5 days 'to complete the course and prevent wound infection'. From an antimicrobial stewardship perspective, what is the most appropriate action?
- A. Support the prescription as it ensures adequate prophylaxis coverage and patient compliance
- B. Suggest extending to 7 days to ensure complete prevention of surgical site infection
- C. Recommend no further antibiotics as single-dose prophylaxis is adequate for clean elective surgery (Correct Answer)
- D. Suggest switching to flucloxacillin for narrower spectrum coverage but continue the 5-day course
- E. Recommend reducing to 3 days of oral antibiotics as a compromise between prophylaxis and stewardship
Explanation: ***Recommend no further antibiotics as single-dose prophylaxis is adequate for clean elective surgery*** - For **clean-contaminated** or **clean elective surgery** like an inguinal hernia repair, a single pre-operative dose of antibiotics is considered sufficient to prevent **Surgical Site Infection (SSI)**. - **Antimicrobial stewardship** principles advocate against prolonged antibiotic courses when not clinically indicated, as this contributes to **antimicrobial resistance** and potential adverse effects such as *Clostridioides difficile* infection. *Support the prescription as it ensures adequate prophylaxis coverage and patient compliance* - This approach is contrary to **antimicrobial stewardship** guidelines for clean surgical procedures, as extended antibiotic courses for uncomplicated cases are not evidence-based and offer no additional benefit. - Unnecessary antibiotic use increases the risk of **adverse drug reactions**, **C. difficile infection**, and fosters the development of **antibiotic-resistant bacteria**. *Suggest extending to 7 days to ensure complete prevention of surgical site infection* - There is no evidence that longer courses of antibiotics are more effective at preventing infection in **uncomplicated elective surgery**. - This action significantly increases the selection pressure for **multi-drug resistant organisms** and unnecessary healthcare costs. *Suggest switching to flucloxacillin for narrower spectrum coverage but continue the 5-day course* - While **narrower-spectrum antibiotics** are generally preferred, no antibiotic course is required post-operatively for this specific procedure, making any continuation inappropriate. - Continuing any antibiotic for 5 days post-discharge in this scenario is considered **inappropriate prescribing** regardless of the spectrum, for a **clean elective surgery**. *Recommend reducing to 3 days of oral antibiotics as a compromise between prophylaxis and stewardship* - A "compromise" duration is not **evidence-based**; if prophylaxis is only needed at induction, any further doses are redundant. - Stewardship focuses on the **optimal duration** of antibiotic use, which in this case is zero further doses once the surgical incision is closed and the patient is stable.
Question 163: What is the recommended first-line oral antibiotic for the treatment of uncomplicated cellulitis in adults according to current UK national guidance?
- A. Co-amoxiclav 625mg three times daily
- B. Flucloxacillin 500mg-1g four times daily (Correct Answer)
- C. Doxycycline 200mg loading dose then 100mg daily
- D. Clarithromycin 500mg twice daily
- E. Cefalexin 500mg three times daily
Explanation: ***Flucloxacillin 500mg-1g four times daily***- **Flucloxacillin** is the recommended first-line agent for uncomplicated cellulitis in the UK (NICE/PHE) as it effectively targets **Staphylococcus aureus** and **Group A Streptococcus**.- Using a narrow-spectrum agent like flucloxacillin promotes **antimicrobial stewardship** by limiting unnecessary coverage and reducing resistance.*Co-amoxiclav 625mg three times daily*- This is a broad-spectrum antibiotic generally reserved for **bites (human or animal)** or cellulitis with specific contamination from soil or water.- It is not recommended for routine uncomplicated cellulitis because it extends coverage to **anaerobes** and gram-negative bacilli unnecessarily.*Doxycycline 200mg loading dose then 100mg daily*- This is usually considered a **second-line** option or an alternative for patients with **penicillin allergy**.- It provides moderate coverage but is not the primary empirical choice for otherwise healthy adults in the UK.*Clarithromycin 500mg twice daily*- Clarithromycin is an alternative treatment option specifically for patients who have a **penicillin allergy**.- While effective against common skin pathogens, it is not first-line due to the preferred efficacy and narrow spectrum of **penicillins**.*Cefalexin 500mg three times daily*- Cefalexin is a **first-generation cephalosporin** that may be used as an alternative, but it is not the gold-standard first-line therapy.- It is often reserved for those with non-severe penicillin allergies or as a second-line oral agent.
Question 164: A hospital trust antimicrobial stewardship team reviews prescribing practices on surgical wards and identifies that 68% of patients receive surgical antibiotic prophylaxis extending beyond 24 hours post-operatively, despite evidence that single-dose prophylaxis is adequate for most procedures. Which quality improvement intervention has the strongest evidence base for reducing inappropriate prolonged surgical prophylaxis?
- A. Monthly educational emails to surgical consultants highlighting guidelines on appropriate prophylaxis duration
- B. Automatic stop orders embedded in electronic prescribing systems that discontinue surgical prophylaxis after 24 hours unless actively renewed with documented indication (Correct Answer)
- C. Quarterly audit and feedback reports sent to surgical departments showing their prophylaxis prescribing patterns
- D. Poster campaigns in surgical areas displaying guidelines for surgical antibiotic prophylaxis
- E. Annual mandatory e-learning modules on antimicrobial stewardship for all surgical staff
Explanation: ***Automatic stop orders embedded in electronic prescribing systems that discontinue surgical prophylaxis after 24 hours unless actively renewed with documented indication***- **Automatic stop orders** are high-leverage interventions that change the **default behavior**, requiring clinicians to actively justify deviations from evidence-based guidelines.- This approach is part of **Computerized Clinical Decision Support (CCDS)**, which has the strongest evidence base for achieving significant and sustained reductions in inappropriate prolonged prophylaxis.*Monthly educational emails to surgical consultants highlighting guidelines on appropriate prophylaxis duration*- Educational emails are considered **passive interventions** and are generally weak at changing long-term clinical behavior when used in isolation.- They do not address the **point-of-care decision-making** process where prescribing errors frequently occur.*Quarterly audit and feedback reports sent to surgical departments showing their prophylaxis prescribing patterns*- While **audit and feedback** is a recognized strategy, its effectiveness is often delayed as it identifies past behaviors rather than preventing errors in real-time.- It is less effective than **structural changes** like electronic stops because it relies on the clinician's motivation to review and act upon old data.*Poster campaigns in surgical areas displaying guidelines for surgical antibiotic prophylaxis*- Posters are a form of **visual aid** with very low evidence for changing complex prescribing habits; they are easily ignored in busy clinical environments.- They lack the **forcing function** needed to stop a clinician from continuing a prophylaxis course unnecessarily.*Annual mandatory e-learning modules on antimicrobial stewardship for all surgical staff*- **E-learning** increases theoretical knowledge but often fails to translate into improved **clinical practice** due to the gap between learning and bedside application.- **Antimicrobial stewardship** guidelines are better implemented through workflow integration rather than periodic mandatory training sessions.
Question 165: A 58-year-old woman with poorly controlled type 2 diabetes (HbA1c 98 mmol/mol) presents with a 24-hour history of rapidly progressive pain, swelling, and discolouration of her left foot following a minor injury 3 days ago. On examination, the foot is grossly swollen, dusky purple with areas of blistering, and there is crepitus on palpation. She appears unwell with temperature 38.9°C, pulse 118 bpm, blood pressure 98/62 mmHg. Blood tests show: WBC 22.4 × 10⁹/L, lactate 4.8 mmol/L, creatinine 156 μmol/L, CK 2,840 U/L. What is the most critical immediate antimicrobial therapy in addition to urgent surgical consultation?
- A. Intravenous flucloxacillin 2g six-hourly and metronidazole 500mg eight-hourly
- B. Intravenous piperacillin-tazobactam 4.5g eight-hourly, clindamycin 600mg six-hourly, and vancomycin 1g twelve-hourly (Correct Answer)
- C. Intravenous co-amoxiclav 1.2g eight-hourly and ciprofloxacin 400mg twelve-hourly
- D. Intravenous meropenem 1g eight-hourly and teicoplanin 400mg twelve-hourly
- E. Intravenous ceftriaxone 2g daily and metronidazole 500mg eight-hourly
Explanation: ***Intravenous piperacillin-tazobactam 4.5g eight-hourly, clindamycin 600mg six-hourly, and vancomycin 1g twelve-hourly*** - This regimen provides comprehensive **broad-spectrum coverage** essential for necrotizing fasciitis, targeting **Gram-positive**, **Gram-negative**, **anaerobic**, and **MRSA** pathogens. - **Clindamycin** is crucial for its ability to inhibit **bacterial toxin production**, which is a significant factor in the rapid tissue destruction seen in necrotizing fasciitis. *Intravenous flucloxacillin 2g six-hourly and metronidazole 500mg eight-hourly* - This combination lacks adequate coverage for **Gram-negative bacteria** and **MRSA**, both of which are common in severe soft tissue infections, especially in diabetic patients. - **Flucloxacillin** primarily covers MSSA and Streptococcus but is insufficient for the broad range of potential pathogens in necrotizing fasciitis. *Intravenous co-amoxiclav 1.2g eight-hourly and ciprofloxacin 400mg twelve-hourly* - This regimen lacks reliable coverage for **MRSA** and may not be sufficient for severe **Pseudomonas aeruginosa** infections or certain resistant Gram-negative organisms. - The anti-toxin effect of **clindamycin** is also missing, which is important in necrotizing infections. *Intravenous meropenem 1g eight-hourly and teicoplanin 400mg twelve-hourly* - While **meropenem** provides excellent broad-spectrum Gram-positive, Gram-negative (including Pseudomonas), and anaerobic coverage, and **teicoplanin** covers MRSA, this regimen lacks the crucial **anti-toxin effect of clindamycin**. - The absence of clindamycin might compromise outcomes in severe necrotizing infections where toxin production plays a key role. *Intravenous ceftriaxone 2g daily and metronidazole 500mg eight-hourly* - This combination provides insufficient coverage for **MRSA** and has limited activity against some severe **Gram-positive infections** (e.g., requiring anti-toxin activity) and certain resistant Gram-negative bacteria. - **Ceftriaxone** alone does not offer the broad-spectrum coverage needed for polymicrobial necrotizing fasciitis, particularly for MRSA and some anaerobes.
Question 166: A 26-year-old man presents with a 4-day history of multiple painful pustular lesions on his forearms, chest, and back. He is an amateur rugby player and reports that several teammates have had similar skin problems. Examination reveals multiple 1-2 cm diameter lesions with surrounding erythema and central pustulation. Some lesions have yellow crusting. Temperature 37.4°C, otherwise systemically well. A swab from one lesion grows Staphylococcus aureus resistant to flucloxacillin but sensitive to erythromycin, doxycycline, and co-trimoxazole. What is the most appropriate management?
- A. Oral flucloxacillin 1g four times daily for 7 days
- B. Topical fusidic acid three times daily for 7 days
- C. Oral doxycycline 100mg twice daily for 7 days and recommend decolonisation for close contacts (Correct Answer)
- D. Intravenous vancomycin as inpatient due to MRSA infection
- E. Oral erythromycin 500mg four times daily and advise wound care only
Explanation: ***Oral doxycycline 100mg twice daily for 7 days and recommend decolonisation for close contacts*** - The patient has **Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA)**, evidenced by flucloxacillin resistance, and doxycycline is an appropriate oral antibiotic for such infections, as confirmed by sensitivity. - Given the cluster of cases in a rugby team, **decolonisation** of close contacts (e.g., with nasal mupirocin and chlorhexidine washes) is essential to prevent further transmission. *Oral flucloxacillin 1g four times daily for 7 days* - The culture results explicitly state the *Staphylococcus aureus* is **resistant to flucloxacillin**, making this antibiotic ineffective for treatment. - Using a resistant antibiotic would lead to treatment failure and potential worsening of the infection. *Topical fusidic acid three times daily for 7 days* - **Topical therapy** is generally insufficient for **multiple, widespread lesions** as seen on this patient's forearms, chest, and back. - In an **outbreak setting** with potentially systemic involvement (mild fever) and community spread, **oral antibiotics** are necessary for effective eradication and control. *Intravenous vancomycin as inpatient due to MRSA infection* - **IV vancomycin** is reserved for severe, invasive, or life-threatening MRSA infections, which is not indicated here as the patient is **systemically well**. - Outpatient management with effective oral antibiotics is appropriate for non-severe CA-MRSA skin and soft tissue infections. *Oral erythromycin 500mg four times daily and advise wound care only* - While sensitive to erythromycin, **macrolide resistance** can develop during treatment with *S. aureus*, making it a less reliable choice than doxycycline in many cases. - Advising **wound care only** is inadequate for widespread CA-MRSA infection and completely ignores the critical need for **decolonisation strategies** in a community outbreak.
Question 167: A hospital antimicrobial stewardship committee is evaluating the impact of a newly implemented antibiotic approval system for restricted antimicrobials. Six months after implementation, audit data shows: total antibiotic prescriptions reduced by 12%, restricted antibiotic use reduced by 35%, mean duration of therapy reduced from 8.2 to 6.4 days, but Clostridioides difficile infection rates increased from 2.1 to 3.8 per 10,000 bed-days. Hospital-acquired bacteraemia rates remain unchanged. What is the most appropriate interpretation of these findings?
- A. The intervention is successful and should be continued without modification as the primary outcomes have improved
- B. The increase in C. difficile infections is likely coincidental and unrelated to the antibiotic stewardship intervention
- C. The intervention requires urgent review and possible modification, as the increase in C. difficile infections suggests unintended consequences that outweigh the benefits (Correct Answer)
- D. The intervention should be discontinued immediately as any increase in healthcare-associated infections is unacceptable
- E. The data is insufficient to draw conclusions and a further 12 months of data collection is required before making any changes
Explanation: ***The intervention requires urgent review and possible modification, as the increase in C. difficile infections suggests unintended consequences that outweigh the benefits*** - A significant increase in **Clostridioides difficile infection** (CDI) rates serves as a critical safety signal and a likely **unintended consequence** of the new stewardship policy. - While primary metrics like **duration of therapy** improved, the team must investigate if clinicians substituted restricted drugs with high-risk alternatives (e.g., fluoroquinolones) that increase **CDI risk**. *The intervention is successful and should be continued without modification as the primary outcomes have improved* - Success in stewardship is measured not just by **volume reduction**, but by overall patient safety and **clinical outcomes**. - Ignoring a nearly twofold increase in **CDI rates** constitutes a failure to respond to a major **healthcare-associated infection** alert. *The increase in C. difficile infections is likely coincidental and unrelated to the antibiotic stewardship intervention* - Changes in **antibiotic pressure** are the most significant modifiable risk factor for CDI, making a temporal association highly likely to be **causal**. - Assuming the increase is **coincidental** without a thorough investigation or root cause analysis is medically and administratively irresponsible. *The intervention should be discontinued immediately as any increase in healthcare-associated infections is unacceptable* - Complete **discontinuation** ignores the positive data, such as shorter **treatment durations** and reduced antibiotic overuse. - The appropriate response is **modification and optimization** rather than total abandonment of a program that has shown efficacy in other metrics. *The data is insufficient to draw conclusions and a further 12 months of data collection is required before making any changes* - Waiting an additional 12 months while **CDI rates** are rising poses an unacceptable risk to **patient safety**. - Six months of data showing a consistent upward trend in infections is sufficient to trigger a **quality improvement investigation**.
Question 168: A 34-year-old woman with a BMI of 38 kg/m² presents to the Emergency Department with a 3-day history of a painful, red, swollen area on the inner aspect of her right thigh. The affected area measures approximately 15 cm × 10 cm, is warm and tender with overlying shiny skin, but there is no fluctuance, crepitus, or systemic upset. Temperature 37.2°C, pulse 78 bpm, blood pressure 128/82 mmHg. What is the most appropriate immediate management according to current UK guidance?
- A. Oral flucloxacillin 500mg four times daily and arrange follow-up in 48 hours (Correct Answer)
- B. Incision and drainage under local anaesthetic in the Emergency Department
- C. Intravenous flucloxacillin 2g four times daily and admit for observation
- D. Oral co-amoxiclav 625mg three times daily and topical fusidic acid
- E. Ultrasound imaging to exclude abscess formation before commencing treatment
Explanation: ***Oral flucloxacillin 500mg four times daily and arrange follow-up in 48 hours***- This patient presents with **uncomplicated cellulitis** (Eron Class I) as evidenced by the lack of **systemic upset**, fever, or unstable comorbidities. This warrants outpatient management.- According to current **UK guidelines** (e.g., NICE), first-line treatment for uncomplicated cellulitis in adults is oral **flucloxacillin** to target common Gram-positive pathogens like *Staphylococcus aureus* and *Streptococcus pyogenes*.*Incision and drainage under local anaesthetic in the Emergency Department*- **Incision and drainage** is the primary treatment for **abscesses**, which are characterized by **fluctuance** (a palpable collection of pus). The clinical description explicitly states there is **no fluctuance**.- Attempting to incise and drain **cellulitis** (diffuse soft tissue infection without pus collection) is inappropriate and can potentially worsen the infection or cause unnecessary tissue damage.*Intravenous flucloxacillin 2g four times daily and admit for observation*- **Intravenous antibiotics** and hospital admission are reserved for more severe cases of cellulitis, such as those with **systemic signs of infection** (e.g., high fever, rigors, hemodynamic instability), rapid progression, or failure of oral therapy (Eron Class II or higher).- This patient is **afebrile** and **hemodynamically stable**, indicating that outpatient oral treatment is appropriate and sufficient.*Oral co-amoxiclav 625mg three times daily and topical fusidic acid*- **Co-amoxiclav** (amoxicillin/clavulanic acid) has a broader spectrum, often reserved for cellulitis secondary to **animal/human bites**, facial cellulitis, or where atypical organisms are suspected, which is not indicated here.- **Topical fusidic acid** is ineffective for cellulitis, which is an infection of the deeper dermis and subcutaneous tissue, requiring systemic antibiotic penetration.*Ultrasound imaging to exclude abscess formation before commencing treatment*- While **ultrasound** can identify occult abscesses, it is generally **not necessary** to delay antibiotic treatment for imaging in a clinically clear case of uncomplicated cellulitis with **no signs of fluctuance**.- Clinical examination is typically sufficient for diagnosing uncomplicated cellulitis, and prompt initiation of **antibiotics** is crucial to prevent progression.
Question 169: According to the UK 'Start Smart - Then Focus' antimicrobial stewardship toolkit, which of the following constitutes a key component of the 'Review' decision at 48-72 hours?
- A. Discontinue all antimicrobials if the patient is afebrile regardless of other clinical parameters
- B. Assess clinical response, microbiology results, and markers of infection to make a documented decision to stop, switch, or continue antibiotics (Correct Answer)
- C. Automatically extend treatment duration by another 48-72 hours if any inflammatory markers remain elevated
- D. Switch all intravenous antibiotics to oral formulations if the patient can tolerate oral intake
- E. Continue current antimicrobial regimen until completion of a minimum 7-day course
Explanation: ***Assess clinical response, microbiology results, and markers of infection to make a documented decision to stop, switch, or continue antibiotics***- The **'Focus'** element of the **'Start Smart - Then Focus'** toolkit mandates a formal review at **48-72 hours** to refine antimicrobial therapy based on evolving clinical and laboratory evidence.- This step ensures a **documented decision** is made among five clinical options: stop, switch (IV to oral), change (narrow/broaden), continue, or move to outpatient parenteral antibiotic therapy (OPAT).*Discontinue all antimicrobials if the patient is afebrile regardless of other clinical parameters*- Fever is only one clinical marker; the decision to stop must also consider **microbiology data**, physical exam findings, and the **site of infection**.- Stopping based solely on temperature ignores the risk of **relapse** or incomplete treatment of deep-seated infections.*Automatically extend treatment duration by another 48-72 hours if any inflammatory markers remain elevated*- Inflammatory markers like **CRP** or **procalcitonin** are non-specific and may remain elevated due to non-infectious inflammation or a lag in physiological recovery.- **Antimicrobial stewardship** discourages automatic extensions, favoring a holistic assessment over reliance on isolated laboratory values.*Switch all intravenous antibiotics to oral formulations if the patient can tolerate oral intake*- While **IV-to-oral switch** is a key component of the 'Review' phase, it is only *one* of the potential decisions, not the *sole* or *defining* component of the entire review process.- The 'Review' decision encompasses a broader assessment to determine whether to stop, switch, change, continue, or move to OPAT, making this option too narrow.*Continue current antimicrobial regimen until completion of a minimum 7-day course*- The 'Start Smart - Then Focus' toolkit emphasizes **individualized treatment duration** based on clinical response and microbiology, not arbitrary minimums.- Continuing for a fixed minimum course without re-evaluation contradicts the **stewardship principle** of optimizing duration to prevent resistance and adverse effects.
Question 170: A 72-year-old man with chronic obstructive pulmonary disease is admitted with an acute exacerbation and started on intravenous co-amoxiclav. On day 4, he develops profuse watery diarrhoea (8 episodes in 24 hours) with cramping abdominal pain. Temperature is 38.3°C, pulse 102 bpm, blood pressure 118/72 mmHg. Examination reveals a diffusely tender abdomen without peritonism. Blood tests show WBC 16.2 × 10⁹/L, CRP 145 mg/L, creatinine 142 μmol/L (baseline 98 μmol/L). According to UK antimicrobial stewardship principles, what is the most appropriate initial management?
- A. Continue co-amoxiclav and add loperamide for symptomatic relief
- B. Stop co-amoxiclav, send stool for Clostridioides difficile toxin, and start oral vancomycin empirically (Correct Answer)
- C. Stop co-amoxiclav, send stool for culture, and await results before starting antibiotics
- D. Continue co-amoxiclav and add oral metronidazole as prophylaxis
- E. Switch co-amoxiclav to intravenous ciprofloxacin and add probiotics
Explanation: ***Stop co-amoxiclav, send stool for Clostridioides difficile toxin, and start oral vancomycin empirically*** - The patient's presentation with profuse watery diarrhoea, cramping abdominal pain, fever, significantly elevated **WBC (16.2 × 10⁹/L)**, high **CRP (145 mg/L)**, and **acute kidney injury (creatinine 142 μmol/L)**, occurring after **co-amoxiclav** use, is highly suggestive of **Clostridioides difficile infection (CDI)**. - UK antimicrobial stewardship principles mandate stopping the inciting antibiotic and initiating **oral vancomycin** empirically for suspected moderate to severe CDI while awaiting **C. difficile toxin** results, due to the high risk of complications. *Continue co-amoxiclav and add loperamide for symptomatic relief* - **Loperamide** is absolutely contraindicated in suspected or confirmed CDI as it can lead to **toxic megacolon** by reducing gut motility and prolonging toxin exposure. - Continuing **co-amoxiclav**, the suspected causative antibiotic, would perpetuate the dysbiosis and worsen the CDI. *Stop co-amoxiclav, send stool for culture, and await results before starting antibiotics* - While stopping the antibiotic is correct, **stool culture** is not the primary diagnostic test for CDI; a specific **Clostridioides difficile toxin assay** is required. - Awaiting results before starting treatment in a patient with significant systemic signs of infection (fever, elevated WBC, acute kidney injury) and severe diarrhoea risks rapid clinical deterioration and adverse outcomes. *Continue co-amoxiclav and add oral metronidazole as prophylaxis* - **Metronidazole** is no longer the first-line treatment for CDI in the UK, especially for moderate to severe cases, and is never used as prophylaxis for suspected CDI. - Continuing the **co-amoxiclav** directly contributes to the pathogenesis of CDI and prevents resolution of the gut flora imbalance. *Switch co-amoxiclav to intravenous ciprofloxacin and add probiotics* - **Ciprofloxacin**, a fluoroquinolone, is among the antibiotics with the highest risk for inducing and exacerbating **Clostridioides difficile infection**. - There is currently insufficient evidence to recommend **probiotics** for the treatment of active CDI, particularly in severe cases.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free